Relapse Clinical Trials in Boston, Massachusetts
50 recruitingBoston, Massachusetts
Showing 1–20 of 50 trials
Recruiting
Phase 3
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Relapsed/Refractory Primary Central Nervous System Lymphoma
Ono Pharmaceutical Co., Ltd.132 enrolled18 locationsNCT07104032
Recruiting
Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839
Recruiting
Phase 1Phase 2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Phase 1Phase 2
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Relapsed/Refractory Non-Hodgkin Lymphoma
Bristol-Myers Squibb308 enrolled65 locationsNCT06090539
Recruiting
Phase 2
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Relapsed or Refractory Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute52 enrolled2 locationsNCT06660368
Recruiting
Phase 1
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Acute Myeloid LeukemiaMyeloid SarcomaAcute Myeloid Leukemia, in Relapse+7 more
Kura Oncology, Inc.420 enrolled44 locationsNCT05735184
Recruiting
Phase 1
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Acute Lymphoblastic Leukemia, in RelapseAcute Leukemia of Ambiguous LineageAcute Lymphoblastic Leukemia With Failed Remission+8 more
Andrew E. Place, MD30 enrolled5 locationsNCT05292664
Recruiting
Phase 2
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
Relapsed Large B-cell LymphomaRefractory Large B-cell Lymphoma
Massachusetts General Hospital30 enrolled2 locationsNCT06811272
Recruiting
Phase 1Phase 2
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 2
Epco, Zanu, Ritux for R/R FL or MZL
Non-Hodgkin LymphomaLymphomaFollicular Lymphoma+3 more
Reid Merryman, MD45 enrolled3 locationsNCT06563596
Recruiting
Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Relapsed or Refractory T Cell Lymphoma
Ono Pharmaceutical Co., Ltd.217 enrolled20 locationsNCT05079282
Recruiting
Phase 1Phase 2
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic LeukemiaLeukemiaRelapsed Leukemia+2 more
Jennifer R. Brown, MD, PhD64 enrolled1 locationNCT06644183
Recruiting
Phase 1
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)
Cullinan Therapeutics Inc.60 enrolled11 locationsNCT05143996
Recruiting
Not Applicable
Novel Digital Application for Patients With Acute Leukemia
High-Risk Acute Myeloid LeukemiaPrimary Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia
Massachusetts General Hospital200 enrolled3 locationsNCT06472128
Recruiting
Phase 1
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Relapsed/Refractory KMT2A-r Acute LeukemiaRelapsed/Refractory NUP98-r Acute LeukemiaRelapsed/Refractory NPM1-m Acute Leukemia
PedAL BCU, LLC20 enrolled20 locationsNCT06376162
Recruiting
Phase 1
IS-free Treg HaploHCT
Myelodysplastic SyndromesStem Cell Transplant ComplicationsGraft vs Host Disease+2 more
Dana-Farber Cancer Institute30 enrolled1 locationNCT04678401
Recruiting
Phase 2
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Relapsed Classic Hodgkin Lymphoma
City of Hope Medical Center31 enrolled5 locationsNCT04561206
Recruiting
Phase 1Phase 2
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Chronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Excess Blasts-2Leukemia, Myeloid, Acute+2 more
Aptose Biosciences Inc.240 enrolled34 locationsNCT03850574
Recruiting
Not Applicable
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Relapsed Adult AMLHigh-Risk Acute Myeloid LeukemiaPrimary Refractory Acute Myeloid Leukemia
Massachusetts General Hospital2,300 enrolled20 locationsNCT05237258
Recruiting
Phase 1
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
Oryzon Genomics S.A.50 enrolled13 locationsNCT05546580